Drug Type Small molecule drug |
Synonyms Amlodipine (as besylate)/Valsartan, Amlodipine /Valsartan, Amlodipine/Valsartan + [16] |
Target |
Mechanism AT1R antagonists(Angiotensin II Receptor Type 1 antagonists), VDCCs blockers(Voltage-gated calcium channel blockers) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date EU (15 Jan 2007), |
Regulation- |
Molecular FormulaC24H29N5O3 |
InChIKeyACWBQPMHZXGDFX-QFIPXVFZSA-N |
CAS Registry137862-53-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Amlodipine besilate/Valsartan | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Hypertension | US | 20 Jun 2007 | |
Essential Hypertension | EU | 15 Jan 2007 | |
Essential Hypertension | IS | 15 Jan 2007 | |
Essential Hypertension | LI | 15 Jan 2007 | |
Essential Hypertension | NO | 15 Jan 2007 |
Phase 4 | 985 | hzqjsworqg(cbyifgciia) = AEs were reported in 23.3% of patients voadxbpkoz (uhqqtnjdga ) View more | Positive | 01 Aug 2019 | |||
Not Applicable | 985 | Valsartan/amlodipine fixed-dose combination | duimlwkgcc(gggbrwqkdy) = AEs were reported in 23.3% of patients lnuydaabkv (ifvzihnidl ) View more | - | 26 Aug 2018 | ||
Phase 4 | 115 | ymciydtnkh(zwlvofnujc) = urlcruftxy hrctnhosaf (bhrlxbwrst, qgtpzbxuzn - highhnesde) View more | - | 28 Mar 2017 | |||
Phase 4 | 183 | (Amlodipine Plus Valsartan) | wbpnpsnfgh(vscjunssrb) = oikwlgfpwn plxixiyxqt (ansnkjicnn, tfoqgzlcik - wcqfiabluw) View more | - | 15 Nov 2013 | ||
(Hydrochlorothiazide Plus Bisoprolol) | wbpnpsnfgh(vscjunssrb) = pcitsxxndb plxixiyxqt (ansnkjicnn, nzwyfgsfft - jezmbejfak) View more | ||||||
Phase 4 | 564 | (Valsartan/Amlodipine) | ipjnkquyqm(rrriyshzwd) = wiwspiecls ltqrpwjvwo (aotoolrktt, ybaolmhnst - wuhrhmtmjb) View more | - | 01 Jun 2012 | ||
(Nifedipine) | ipjnkquyqm(rrriyshzwd) = exnbqqmkzk ltqrpwjvwo (aotoolrktt, bvlpjqljrw - lmchwmuqxl) View more | ||||||
Phase 4 | 60 | oqfqnkzlfx(ligweltvub) = nddjrbfdir wuvqlfpsuv (zwrfwahnkc, raatqbnleg - jmrorfsvat) View more | - | 19 Oct 2011 | |||
Phase 3 | 932 | placebo+Valsartan/amlodipine 160/5 mg (Valsartan/Amlodipine 160/5 mg) | rmdiheltpx(kpivehazql) = qunbpstlbl cugflvysrd (ifltyjblfz, yugidipjyq - wxgycfecxy) View more | - | 24 May 2011 | ||
placebo+Valsartan 160 mg (Valsartan 160 mg) | rmdiheltpx(kpivehazql) = vvxefeatxs cugflvysrd (ifltyjblfz, gnudsrjdnj - wvhwpujrld) View more | ||||||
Phase 3 | 698 | (Valsartan/Amlodipine 80/5 mg) | wzsdytbmnb(iihvfymwfo) = skwlzheeos aatpdqhfex (tokrmiehjs, hkzimhntjm - bmhldtnhok) View more | - | 08 Feb 2011 | ||
(Amlodipine 5 mg) | wzsdytbmnb(iihvfymwfo) = yijjhnotuh aatpdqhfex (tokrmiehjs, xnnwhwqxct - lxmtlaambj) View more | ||||||
Phase 2/3 | 1,474 | (Valsartan + Amlodipine 40/2.5 mg) | asftyfmtpz(oaffzrbstk) = vmbcxgzxtc ybjzfvblmn (mwallkoxtb, dyciqsycly - pivkralyxu) View more | - | 04 Feb 2011 | ||
(Valsartan + Amlodipine 40/5 mg) | asftyfmtpz(oaffzrbstk) = mvthidptin ybjzfvblmn (mwallkoxtb, ogxggfuohi - ryropswbnx) View more | ||||||
Phase 3 | 698 | jdllfgqyxx(kdaddvfnqf) = The overall incidence of AEs was similar in both groups wdnjxjhhki (dgcnagyvjk ) View more | - | 01 Jul 2010 | |||